Cook starts clinical trial of Logic stent:
This article was originally published in Clinica
Executive Summary
Cook is to begin a multicentre clinical trial of its Logic coronary stent, under an investigational device exemption from the US FDA. The trial will include 400 patients with de novo lesions and 300 patients with acute and threatened vessel closure. The Logic stent, which consists of a slotted tubular design, is premounted on a 135cm balloon catheter that is compatible with a 0.014 inch guidewire. It is available in lengths of 10mm and 15mm. Results from the trial will form the basis of a PMA application to the FDA, says the Bloomington, Indiana company.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.